Skip to main content

BioFi AG newly settles in Basel

| News

BioFi AG newly settles in Basel


BioFi has set up its headquarters in Basel. The company has emerged from Crowley Davis Research, which was established in the US state of Idaho in 2000. Using its proprietary technologies, BioFi operates the CellSim platform, which can be used to model and simulate living organisms.

The newly established company BioFi AG has settled in Basel. It brings with it the technological heritage of US company Crowley Davis Research Inc, which is being dissolved, and operates a proprietary, trademarked platform called CellSim. This provides virtual modeling and simulation solutions for living organisms, ranging from single-cell organisms to advanced cancer tissue. The application areas include drug discovery and development and synthetic biology.

Intersection of biology and computer science

Bill Crowley, CEO of Crowley Davis Research and CFO of BioFi AG, commented: “The Basel Area is now home for this collection of proprietary technologies and quite fittingly so; the area is ground zero for exactly the kinds of talent and resources the company needs to achieve its highest and best use in science.” CEO of BioFi AG Thomas Nirnberger adds: “As one of the leading life sciences and technology clusters in Europe, the Basel Area is a natural location to grow a business at the intersection of biology and computer science.”

BioFi’s settlement has been supported by the location and innovation promotion agency Basel Area Business & Innovation and Switzerland Innovation.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More